News About: Pharm. Industry
Who will lead KPBMA’s ethical management to eradicate illegal rebates?
The ‘National Industry Power Strengthening’ process that the former Chair Heng-Myung Lee and Chairman Hee-Mok Won have carried out will continue while Jung-Hee Lee, Chair of the Korea Pharmaceutical and Bio-Pharma Ass...
Hanmi Pharm awarded ‘BPW Gold Award’ for first time as pharma
Hanmi Pharm(CEO Jong-Su Woo, Sae-Chang Kwon) has been awarded the 24th ‘BPW Gold Award’ by the Business & Professional Women Korea(BPW Korea) for the first time as a Korean pharmaceutical company.
The award establish...
Dong Wha Pharm’s ‘Zabolante’ and Ildong’s ‘Besivo’ selected New Drug Development Awards
The Korea Drug Research Association(Chairman Dong-Yeon Kim, KDRA) will hold the ‘19th Korea New Drug Development Awards’ at the Geranium Hall of Hotel Samjung on 27 February, 3pm.
The companies which will receive the...
In 2017, drugs exports were USD 3.2252 billion, increased by 17.2% compared to year before
Although the balance of drug trade recorded deficits last year, the deficit range was decreased by 11.5% compared to the year before.
According to the tendency of import and export published by the Korea Customs Serv...
‘Cutting Drug Price, instead of Suspending Insurance Benefits, on Illegal Rebate Drugs’ passed Health and Welfare Committee
The National Health Insurance Act, which cuts drug price instead of suspending health insurance benefits on drugs with illegal rebates, has passed the Health and Welfare Committee.
The National Assembly Health and We...
KPBMA completes forming the executives with Chair Jung-Hee Lee’s leadership
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA) with the Chair Jung-Hee Lee’s leadership has had new executives.
The KPBMA held the 73rd ordinary general meeting on the 23rd, appointed 13 vic...
Celltrion Healthcare starts to expand business into the Latin America
Celltrion Healthcare has started the engine to enlarge its market share in the Latin American market by signing a distribution and sales agreement of ‘Truxima(generic name: rituximab),’ a biosimilar for the treatment ...
Samsung Biologics signs a contract manufacturing agreement of KRW 17.8 billion with U.S. pharma
Samsung Biologics announced conclusion of a contract manufacturing agreement with a U.S. pharmaceutical company on 21 February.
The agreed payment is approximately KRW 17.8 billion(6.06% of recent sales), and the sta...
7 pharmaceutical companies at most to achieve KRW 1 trillion sales this year
There will be much more pharmaceutical companies with more than KRW 1 trillion sales this year. While there were only 3 pharmaceutical companies last year, it seems the number will get enlarged to 7 companies at most....
SCD Pharm signs total KRW 700 billion export agreement with U.S. Glenmark
Sam Chun Dang Pharm(CEO Jeon-Kyo Park, SCD Pharm) signed a export agreement of its generic eye drop with U.S. Glenmark on the 20th. The export agreement is the 2nd largest export agreement after the last KRW 400 billi...
